Janssen Pharmaceutica Nv

Other

Michael Gaul

Lily Lee Searle

Guozhang Xu

Alexander Y Kim

Dionisios Rentzeperis

Xizhen Zhu

Kevin Douglas Kreutter

Dana L Johnson

Raymond Joseph Patch

Robert W Tuman

Nand Baindur

Christian Andrew Baumann

Dionisois Rentzeperis

Gilles C Bignan

Bao-Ping Zhao

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-&#x3b1; modulators

Substituted phenoxy aminothiazolones as estrogen related receptor-&#x3b1; modulators

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I': Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor

Substituted phenoxy thiazolidinediones as estrogen related receptor-&#xe1; modulators

The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R, R, R, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Alkylquinoline and alkylquinazoline kinase modulators

The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for Hreceptor activity modulation and the treatment of states mediated by histamine Hreceptor activity.

[object Object]

Substituted phenoxy thiazolidinediones as estrogen related receptor-&#x3b1; modulators

The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: wherein R, R, R, and X are as defined herein, the use of such compounds in the synthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis

In an above ground crypt structure, a crypt front or cover slab hanging or supporting arrangement allowing easy installation of the crypt covers and designed when used with a plurality of adjacently disposed crypt covers to allow the outer surfaces of the plurality of crypt covers to define a substantially planar surface.

Crypt structure

A modular crypt system has adjacent columns comprised of substantially 'inverted L' shaped modules, each module having substantially planar vertical and horizontal legs joined at ends thereof to define a corner. A corner reinforcement portion is provided on the inside adjacent surfaces of the legs, together with a notch portion on the outer edge of the vertical leg and adjacent the reinforcement portion. A tongue portion is formed at a free end of the module horizontal leg. The tongue portion of one module is supported in notch portions of an adjacent module. A column of stacked vertical end members is provided adjacent one of the modular columns with each vertical end member having a notch portion at a top end which support the tongue portion of adjacent 'inverted L' shaped modules. A building roof is principally supported by the modular columns and end members.

Growing community of inventors

Yardley, PA, United States of America

Michael Gaul